Aflibercept 18 October 2024 | Regeneron Announces 3-Year Results for High Dose Eylea® (Aflibercept) On 18 October...

Home / News / Pearce IP Blog
Aflibercept 18 October 2024 | Regeneron Announces 3-Year Results for High Dose Eylea® (Aflibercept) On 18 October...
Aflibercept 8 October 2024 | AU | Bayer’s High Dose Eylea® (Aflibercept) PFS Approved in Australia On 8 October 2024,...
On 18 June 2024, Justice Burley delivered a decision regarding documentary discovery in the long running dispute between Pfizer (Pfizer Ireland Pharmaceuticals and Pfizer Australia) and four of its competitors over AU2005280034 for the “Production of polypeptides” (the Pfizer Patent).
On 18 June 2024, Justice Burley delivered a decision regarding documentary discovery in the long running dispute between Pfizer (Pfizer Ireland Pharmaceuticals and Pfizer Australia) and four of its competitors over AU2005280034 for the “Production of polypeptides” (the Pfizer Patent).
On 18 June 2024, Justice Burley delivered a decision regarding documentary discovery in the long running dispute between Pfizer (Pfizer Ireland Pharmaceuticals and Pfizer Australia) and four of its competitors over AU2005280034 for the “Production of polypeptides” (the Pfizer Patent).
Aflibercept 23 September 2024 | Positive 52-Week, Ph 3 Results for Celltrion’s Aflibercept Biosimilar On 23 September...
On 18 June 2024, Justice Burley delivered a decision regarding documentary discovery in the long running dispute between Pfizer (Pfizer Ireland Pharmaceuticals and Pfizer Australia) and four of its competitors over AU2005280034 for the “Production of polypeptides” (the Pfizer Patent).
The Federal Court has continued its run of decisions on contested costs orders. The cost of litigating patent disputes in the Federal Court is high. To maximise the costs recovered, parties are issuing Notices of Offer (pursuant to the Federal Court Rules) and Calderbank letters. These are designed to put the other party at risk of an indemnity costs order should they reject the offer and the first party ultimately receives a more favourable judgment. Indemnity costs orders enable a successful party to claw back up to 100% of their legal costs, whereas a party/party costs order typically only provides a successful party with around 60% of their actual legal costs. So, significant sums of money can be at stake as a result of an effective or ineffective Notice of Offer or Caldberank letter.
Aflibercept 19 September 2024 | EU | Sandoz & Samsung Bioepis/Biogen Aflibercept Biosimilars Recommended in Europe...
The battle to claim the earliest valid patent rights to CRISPR gene-editing technology has been fought around the world. In Australia, the most protracted dispute…
Aflibercept 13 September 2024 | KR | Alteogen Submits Application for Biosimilar Aflibercept in Korea On 13 September...
Adalimumab 1 September 2024 | AU | Pfizer’s Biosimilar Adalimumab PBS-Listed in Australia On 1 September 2024, the PBS...
CQMS has successfully opposed ESCO Group’s (ESCO) patent application AU 2018201726 (‘726) on the grounds of lack of support and sufficiency. We previously reported on an opposition between the same parties for a related patent family member AU 2018201710 (‘710). As with that case, the Delegate in the present opposition exercised his authority under section 60(3) of the Patents Act 1990 and raised the additional opposition ground of inutility, which was not asserted by CQMS.
16 August 2024 | AU | Janssen Sues Samsung Bioepis for Patent Infringement in Australian Court On 16 August 2024,...
9 August 2024 | Sandoz Reports Q2/24 and Half Year Financial Results - 37% Biosimilar Growth On 9 August 2024, Sandoz...
2 August 2024 | AU | Novo Nordisk Launches Wegovy® (Semaglutide) in Australia On 2 August 2024, Australia’s...